The benchmark S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) has followed the lead of international markets and in afternoon trade finds itself down a disappointing 0.8% to 5,730 points.
Four shares which haven't let this hold them back are listed below. Here's why they are finishing the week with a bang:
The Pro Medicus Limited (ASX: PME) share price has climbed 4% to $5.10 after the healthcare software company released its preliminary final results. Despite the impact of currency headwinds, Pro Medicus delivered an impressive 46.4% lift in net profit after tax to $9.3 million. I think this solid result and its positive outlook could mean the company is worth considering as a buy and hold investment.
The Bubs Australia Ltd (ASX: BUB) share price has rebounded from yesterday's heavy decline and is up 6.5% to 65 cents. This morning the baby food and infant formula company announced the appointment of Dennis Lin as Chairman of the Bubs Australia Board. Mr Lin is also a partner at BDO, where he leads the firm's China Advisory Services team. Investors appear to believe this experience will be very useful given Bubs' aim of penetrating the lucrative Chinese infant formula market.
The Kogan.com Ltd (ASX: KGN) share price is up 6% to $2.54 following the release of its full-year results. The online retailer smashed its prospectus forecasts and reported pro forma net profit after tax growth of 800% to $7.2 million. This was driven by a 30% increase in its customer base and strong growth from its private label products.
The Tatts Group Limited (ASX: TTS) share price is up 3.5% to $4.16 thanks partly to a research note out of Deutsche Bank. According to the note, its analysts have retained their buy rating and $4.67 price target following the release of the lottery operator's full-year results. Tatts delivered a result ahead of Deutsche's expectations.
